Among patients with CN-AML, the pooled ORs of TET2 mutation for CR rate were 0.803 (95%CI: 0.562–1.147; P = 0.228; heterogeneity: I2 = 39.0%, P = 0.161; Fig. 3a). This evidence concerns the gene TET2 and acute myeloid leukemia.